Average 21% body-weight loss in 72 weeks. The molecule US clinics charge $1,200/month for. Compounded in Medellín. Lab-documented.
Average body-weight loss at 72 weeks (SURMOUNT-1)
Receptor agonist (GLP-1 + GIP)
What US wellness clinics charge per month. You'll pay $120.
Tirzepatide is the active ingredient in Mounjaro and Zepbound. It activates two metabolic receptors (GLP-1 and GIP) that control hunger, satiety, glucose, and fat metabolism. The SURMOUNT-1 trial (NEJM, 2022) showed an average 20.9% body-weight loss at the highest dose over 72 weeks — the strongest weight-loss result for any FDA-approved medication at the time of publication.
In the US, getting it costs $1,000–$1,500/month at a compounding pharmacy or $1,400/month for branded Mounjaro. We deliver the identical molecule at roughly one-quarter the US price. No clinic markup, no consultation upsell.
You have 20+ pounds to lose. You want a proven molecule with years of clinical data. You're ready to titrate up slowly. You want a fair source for the molecule, not a Telegram channel or a US clinic markup.
You have MTC or MEN2 history. Active pancreatitis or gallbladder issues. Pregnancy or breastfeeding. Severe gastroparesis. Please review these with your own doctor before ordering.
Drawn from the SURMOUNT-1 published data. Real outcomes vary; titration is something to work out with your own doctor.
Cravings quiet down. Portion sizes drop without willpower. Mild nausea common in week 1.
Energy stable. Clothes loose. Metabolic markers improving.
Body composition transformation visible. Long-term habits rebuilt around lower appetite.
SURMOUNT-1 endpoint at highest dose. Maintenance protocol designed during taper.
It's not magic. It's regulatory and economic structure. US compounding pharmacies operate under FDA enforcement risk that adds 60–70% to their cost basis. Operating cost in Colombia is meaningfully lower, and we are not a venture-funded telehealth company recouping marketing spend. The molecule is the same.
Most are GI and dose-related. The SURMOUNT trials report them in detail. Your own doctor walks you through every one during intake and during dose escalations.
Nausea · Diarrhea · Constipation · Decreased appetite (the point) · Burping · Fatigue in early titration
Pancreatitis (rare) · Gallbladder disease · Severe gastroparesis · Allergic reactions · Hypoglycemia if combined with insulin
Severe persistent abdominal pain · Vomiting that won't stop · Signs of allergic reaction · Severe hypoglycemia symptoms. Call your local emergency services first, then your own doctor. We are a supplier, not a medical provider.
Everything included. Lab-documented vial, supplier COA, cold-chain delivery within Colombia, and WhatsApp support.
$480.000 COP / 4 weeks
10mg vial · 2.5mg–5mg starting dose · supplier COA · Shipping (launch pricing)
$880.000 COP / 4 weeks
15mg vial · 7.5–15mg therapeutic dose · COA included · Priority WhatsApp (launch pricing)
Tirzepatide is sold as research-grade material Branded Mounjaro and Zepbound are Eli Lilly products and unrelated to this compounded preparation. Cited weight-loss percentages reference Jastreboff et al., 2022 (NEJM, SURMOUNT-1); individual results vary. Not for use in pregnancy, breastfeeding, MTC/MEN2 family history, active pancreatitis, or severe gastroparesis. Discuss your medical history with your own doctor before use.